BR112013013469A2 - cápsula farmacêutica oral, método para tratar hiperfosfatemia em um paciente, método para tratar um paciente e pó farmacêutico oral - Google Patents

cápsula farmacêutica oral, método para tratar hiperfosfatemia em um paciente, método para tratar um paciente e pó farmacêutico oral

Info

Publication number
BR112013013469A2
BR112013013469A2 BR112013013469A BR112013013469A BR112013013469A2 BR 112013013469 A2 BR112013013469 A2 BR 112013013469A2 BR 112013013469 A BR112013013469 A BR 112013013469A BR 112013013469 A BR112013013469 A BR 112013013469A BR 112013013469 A2 BR112013013469 A2 BR 112013013469A2
Authority
BR
Brazil
Prior art keywords
patient
oral pharmaceutical
treating
hyperphosphatemia
capsule
Prior art date
Application number
BR112013013469A
Other languages
English (en)
Inventor
David Pierce
Roger Withington
Original Assignee
Shire Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Llc filed Critical Shire Llc
Publication of BR112013013469A2 publication Critical patent/BR112013013469A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112013013469A 2010-12-01 2011-11-30 cápsula farmacêutica oral, método para tratar hiperfosfatemia em um paciente, método para tratar um paciente e pó farmacêutico oral BR112013013469A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/958,380 US8263119B2 (en) 2010-12-01 2010-12-01 Capsule formulations containing lanthanum compounds
PCT/US2011/062716 WO2012075194A1 (en) 2010-12-01 2011-11-30 Capsule and powder formulations containing lanthanum compounds

Publications (1)

Publication Number Publication Date
BR112013013469A2 true BR112013013469A2 (pt) 2016-10-18

Family

ID=45418780

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013013469A BR112013013469A2 (pt) 2010-12-01 2011-11-30 cápsula farmacêutica oral, método para tratar hiperfosfatemia em um paciente, método para tratar um paciente e pó farmacêutico oral

Country Status (10)

Country Link
US (1) US8263119B2 (pt)
EP (1) EP2645995A1 (pt)
JP (5) JP2013544287A (pt)
KR (1) KR20130119960A (pt)
CN (2) CN103237543A (pt)
AU (1) AU2011336602B2 (pt)
BR (1) BR112013013469A2 (pt)
CA (1) CA2816626C (pt)
IL (1) IL226020A0 (pt)
WO (1) WO2012075194A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10612189B2 (en) 2015-04-24 2020-04-07 Honeywell International Inc. Composite fabrics combining high and low strength materials
US10058569B2 (en) 2015-06-24 2018-08-28 Lupin Limited Lanthanum carbonate compositions
CN105125575B (zh) * 2015-08-07 2018-06-08 康臣药业(内蒙古)有限责任公司 一种治疗高磷酸盐血症药物的制备方法
US10272640B2 (en) 2015-09-17 2019-04-30 Honeywell International Inc. Low porosity high strength UHMWPE fabrics
JP6623753B2 (ja) * 2015-12-28 2019-12-25 ニプロ株式会社 炭酸ランタンを含む口腔内崩壊錠
JP2022516567A (ja) * 2019-01-04 2022-02-28 ケイデンス ファーマ アーセー リン吸着剤とビタミンｋとの併用療法
TR201901877A2 (tr) * 2019-02-07 2019-04-22 Hacettepe Ueniversitesi Lantan karbonatin bi̇yoakti̇vi̇tesi̇ni̇ artiran formülasyonlar ve hazirlama yöntemleri̇
WO2021011538A1 (en) * 2019-07-15 2021-01-21 R.P. Scherer Technologies, Llc Capsule dosage forms, methods of preparation and methods of use thereof
EP4061340A4 (en) * 2019-11-21 2023-08-09 Santa Farma Ilaç Sanayi A.S. ORAL SOLID PHARMACEUTICAL COMPOSITIONS WITH LANTANHANE CARBONATE OCTAHYDRATE
CN114247392B (zh) * 2022-01-18 2024-01-05 合肥学院 一种具有三维多孔结构的氧化镧微球及其制备方法
CN115813867B (zh) * 2022-12-01 2024-05-24 山东齐都药业有限公司 碳酸镧冻干片及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4428927A (en) * 1981-05-11 1984-01-31 R. P. Scherer Corporation Masticatory soft elastic gelatin capsules and method for the manufacture thereof
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
GB9506126D0 (en) 1995-03-25 1995-05-10 Johnson Matthey Plc Pharmaceutical composition and method
AU4278301A (en) * 2000-03-27 2001-10-08 Kyowa Hakko Kogyo Co. Ltd. Easy-to-take granule
US7381428B2 (en) 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
EA012798B1 (ru) 2003-08-26 2009-12-30 Шир Холдингз Аг Фармацевтический состав, содержащий карбонат лантана (варианты)
US20060153932A1 (en) 2004-07-27 2006-07-13 Shire Pharmaceuticals, Inc. Method of treating hyperphosphataemia using lanthanum hydroxycarbonate
US20060177415A1 (en) * 2004-11-01 2006-08-10 Burke Steven K Once a day formulation for phosphate binders
EP2050447B1 (en) * 2005-06-08 2017-10-11 Orion Corporation An entacapone-containing oral dosage form
US20070104799A1 (en) * 2005-11-09 2007-05-10 Shire International Licensing B.V. Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
US20070259052A1 (en) 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
EP1938804A1 (en) * 2006-12-22 2008-07-02 Novartis AG Pharmaceutical formulation comprising neurokinin antagonist
EP2389070B1 (en) 2009-01-21 2013-07-31 Mylan Inc. Disintegrable formulations of lanthanum carbonate
WO2010106557A2 (en) 2009-03-20 2010-09-23 Panacea Biotec Limited Stable pharmaceutical formulations comprising anhydrous lanthanum carbonate and process for preparation thereof

Also Published As

Publication number Publication date
CA2816626A1 (en) 2012-06-07
AU2011336602A1 (en) 2013-05-30
EP2645995A1 (en) 2013-10-09
JP2013544287A (ja) 2013-12-12
JP2018030873A (ja) 2018-03-01
KR20130119960A (ko) 2013-11-01
IL226020A0 (en) 2013-06-27
JP6637937B2 (ja) 2020-01-29
WO2012075194A1 (en) 2012-06-07
AU2011336602B2 (en) 2017-06-08
CA2816626C (en) 2019-04-23
JP2023073349A (ja) 2023-05-25
CN105943554A (zh) 2016-09-21
JP2020063292A (ja) 2020-04-23
US8263119B2 (en) 2012-09-11
CN103237543A (zh) 2013-08-07
US20120141580A1 (en) 2012-06-07
JP2022027979A (ja) 2022-02-14

Similar Documents

Publication Publication Date Title
BR112013013469A2 (pt) cápsula farmacêutica oral, método para tratar hiperfosfatemia em um paciente, método para tratar um paciente e pó farmacêutico oral
HK1222811A1 (zh) 用於吸入器的劑量計數器、吸入器及其軸
IL222012A (en) Controlled-release dosage forms for high-dose hygroscopic and water-soluble pharmaceuticals
BR112015010501A2 (pt) composto, composição farmacêutica, nanopartículas, método para tratar câncer em um paciente e composição liofilizada
BR112013033078A2 (pt) partícula, composição farmacêutica, conjunto para o tratamento do câncer e método para o tratamento do câncer em um paciente
BRPI1007636A2 (pt) Composição farmacêutica, forma de dosagem, método para a preparação da composição farmacêutica, método de preparação da forma de dosagem e método de tratamento da dor
BR112015000441A2 (pt) imunoconjugados, formulação farmacêutica e método de tratamento e método para inbir a proliferação de uma célula positiva para cd22
BR112012018947A2 (pt) composição farmacêutica para tratamento e\ou prevenção do cancêr
SG11201504872YA (en) Computer-implemented method, system, and apparatus for electronic patient care
EP2881395A4 (en) PIPERAZINOTRIZOLE COMPOUND, PROCESS FOR PREPARING THE SAME AND USE THEREOF IN THE PREPARATION OF MEDICAMENT
BR112013014583A2 (pt) composição farmacêutica, e, métodos para o tratamento de inflamação, para o tratamento da dor, e para preparar 3-metanossulfonilpropionitrila
IL225597A0 (en) Pharmaceutical preparation, methods of treatment and its uses
BRPI1013089A2 (pt) alimento medicinal, e, métodos para preparar um alimento medicinal, e para tratar um distúrbio metabólico
IL221166A0 (en) System and method for administering medicaments to a patient
BR112012031836A2 (pt) combinação farmacêutica para o tratamento da dor
EP2609846A4 (en) ENCAPSULATED MEDICAL DEVICE AND METHOD OF MANUFACTURING THEREOF
BR112013010102A2 (pt) microagulha, arranjo de microagulhas, dispositivo de microagulhas, e, método para administrar um agente medicinal
HK1183228A1 (zh) 口服藥物治療方法和組合物
HK1161681A1 (en) An oral liquid preparation for treating indigestion and couch in children and a manufacture method thereof
EP2786982A4 (en) AMINO-PROPYLENE-GLYCOL DERIVATIVES, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF
HRP20180793T1 (hr) Farmaceutski pripravak i oblik doziranja koji sadrži dronedaron, te postupak njegove priprave
EP2601955A4 (en) ADSORBENT FOR ORAL ADMINISTRATION, MANUFACTURING METHOD THEREOF AND MEDICAMENT USING THE SAME
EP2865666A4 (en) HEXAHYDROPENTALENE DERIVATIVES, METHOD OF MANUFACTURE AND USE IN MEDICINE
ZA201303695B (en) Pharmaceutical composition comprising citrate and bicarbonate salts,and use thereof for treating cystinuria
LT2806880T (lt) Farmacinė kompozicija, kaip substancija antacidiniam vaistui nuo refliukso

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]